Maxwell Biosciences, Inc.

Maxwell's vision is to create health for the world safely and affordably. That vision fuels our mission: to prove our first-in-class, CLAROMER® brand biomimetic drug discovery platform produces therapeutics that are impactful and lucrative; that is: safe, effective, and highly attractive to clinicians, payers and patients.

Recent News

Biotech Startup Maxwell Biosciences Selected to Present at the Angel Capital Association 2023 Summit

Austin, Texas--(Newsfile Corp. - May 11, 2023) - The Angel Capital Association (ACA) will host "ACA 2023 - The Summit of Angel Investing" (ACA Summit) from May 16-18 in Las Vegas. The flagship angel investing event of the year will bring together angel investors from across North America to learn from industry experts and network with a diverse investor community to support better investment decisions. During the ACA's Innovation Funders Showcase, Maxwell Biosciences (Maxwell), a preclinical...

2023-05-11 11:00 AM EDT

Maxwell Biosciences Announces the Appointment of Maxie McFarland, MBA, as Senior Vice President of Corporate Development and Investor Relations

Austin, Texas--(Newsfile Corp. - April 25, 2023) - Maxwell Biosciences ("Maxwell"), a preclinical drug discovery platform company focused on the development of synthetic compounds that mimic existing human biomolecules (biomimetic therapeutics) from our innate immune system, today announced the appointment of Maxie McFarland, MBA, as Senior Vice President of Corporate Development and Investor Relations. Maxie brings more than 20 years of diverse experience in corporate development and...

2023-04-25 10:00 AM EDT

Ready to Announce with Confidence?

Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us